Stevanato Group S.p.A. Company Analysis & Research
Stevanato Group is a global leader in pharmaceutical drug containment, drug delivery, and diagnostic solutions with a 75-year heritage. The company serves biopharma, biotech, and life sciences companies by providing integrated solutions across the entire drug lifecycle, from development through commercial stages.
Stevanato leverages deep expertise in precision glass manufacturing combined with cutting-edge engineering to provide value-added solutions for injectable biologics and biosimilars. The company is strategically positioned around high-value solutions (now representing 49% of revenue), with significant capacity expansion underway at Latina and Fishers facilities to capitalize on growing demand for self-administration and ready-to-use drug platforms.
Company Overview
Founded: 1949. Headquarters: Piombino Dese, Italy. Revenue: €1.17B. Market Cap: $4.37B. Ticker: STVN (NYSE).
Industry
Pharmaceutical Packaging & Drug Delivery Systems
Cyborg Score: 6/10 — Solid
Well-positioned in high-growth pharma segments with operational leverage potential, but execution risk on capacity ramps and macro headwinds warrant cautious approach.
Strong fundamentals with 9% Q3 2025 revenue growth and 47% high-value solutions expansion. However, near-term headwinds include Engineering segment challenges (19% decline), capital intensity pressuring free cash flow, and customer concentration risk. Capacity expansion provides medium-term upside if utilization improves.
Key Strategic Insights for Stevanato Group S.p.A.
- High-value solutions achieving record 49% of Q3 2025 revenue with 47% growth driven by Nexa syringes and EZ-fill vials, signaling successful product mix shift
- FY2025 guidance of €1.16-1.19B revenue and 43-44% high-value mix indicates management confidence despite tariff and FX headwinds
- Engineering segment facing 19% revenue headwinds with delayed order conversion, suggesting temporary operational challenges requiring resolution
- Strategic partnerships expanding (Datwyler collaboration on large-volume drug delivery), positioning for biosimilars and self-administered therapy trends
Recent Developments
- (November 2025) Q3 2025 revenue €303.2M (+9% YoY); high-value solutions grew 47%; adjusted EBITDA margin improved 280bps to 25.7%
- (January 2026) Strategic collaboration with Datwyler and LTS Device Technologies on large-volume subcutaneous drug delivery for home use
- (Q3 2025) Gross profit margin expanded 240bps to 29.2%; Engineering segment declined 19% with recovery timeline uncertain
Competitors & Competitive Landscape
- West Pharmaceutical Services — Leading supplier of containment solutions for pharma
- SCHOTT Pharma AG & Co. KGaA — Precision glass packaging for pharmaceuticals
- Pro-Dex — Precision engineering for medical/pharma devices
Stevanato competes in the pharmaceutical packaging and drug delivery ecosystem against specialized competitors including West Pharmaceutical Services (prefillable syringes), SCHOTT Pharma (glass containers), and Pro-Dex (engineering services). Stevanato's competitive advantage lies in its integrated end-to-end portfolio spanning containment, delivery systems, diagnostics, and manufacturing services across multiple segments, allowing customers single-source solutions.
More Company Research
Ovid Therapeutics Inc. Fenix Resources Ltd Orion Group Holdings, Inc. Alerus Financial Corporation Riverstone Holdings Limited Watches of Switzerland Group PLC Clas Ohlson AB Mitsubishi Motors Corporation Danske Bank A/S International Games System Co., Ltd. Strabag SE Trimble Inc. Fastenal Company AquaBounty Technologies, Inc. Instil Bio, Inc.Full Company Research Reports
Looking for a more in-depth analysis of Stevanato Group S.p.A.? AskCyborg's Company Research section contains full AI-generated reports with detailed financials, strategic analysis, and Cyborg Score ratings. Browse the complete company research library or explore industry research reports.
AskCyborg provides AI-powered company research and analysis. Visit AskCyborg for full reports, Cyborg Score ratings, and analyst podcasts.